A Danish biotechnology company experienced its worst trading session ever on Friday as investors reacted harshly to underwhelming clinical trial data for its weight loss medication.
Zealand Pharma’s stock price collapsed by more than 30% after the company revealed that petrelintide, an obesity treatment being developed alongside pharmaceutical giant Roche, produced modest results in its mid-stage testing phase.
The clinical study, which tracked 493 participants over 42 weeks, showed patients achieved weight reduction of up to 10.7% when using the experimental medication, according to data published Thursday.
However, these findings pale in comparison to competing obesity therapies currently under development. Eli Lilly’s amylin-based treatment candidate demonstrated weight loss reaching 20.1% in similar mid-stage clinical testing, setting a much higher benchmark.
The competitive landscape for obesity medications has become increasingly demanding, with pharmaceutical companies vying for market share in what analysts project could become a multi-billion dollar annual industry.
This latest disappointment mirrors recent struggles faced by Novo Nordisk, whose stock value dropped significantly last month when their advanced obesity treatment failed to match Lilly’s performance in direct comparison studies.
During early trading in Copenhagen, Zealand’s shares dropped to their lowest point since August 2023, eliminating approximately 8.3 billion Danish crowns (equivalent to $1.3 billion) from the company’s total market capitalization.
Investment firm Jefferies noted in their client advisory: “Potential for Wegovy-like efficacy, but with placebo-like tolerability does suggest this is a viable drug, though likely viewed as 2nd-best to Lilly’s elora for now.”
KBC Securities shared similar sentiments, proposing that petrelintide might find better application in helping patients maintain weight loss rather than initial treatment.
“We think this outcome makes first line positioning difficult,” analysts at the Belgian financial services firm stated.
Roche entered into a collaborative agreement with Zealand in March 2025 to jointly advance petrelintide’s development, with company representatives characterizing the partnership as a “nearly perfect fit” for challenging the current obesity treatment market leaders.
